This is consistent with previous studies that have documented younger age at diagnosis, larger tumor size, lymphovascular invasion and higher grade at diagnosis among TN BC cases [37–40] and those HER-2+ [37, 41, 42] as compared to those with Luminal-A disease. This evidence concerns the gene ERBB2 and breast cancer.